Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.

Persson EK, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier JM, Deswarte K, Verschueren KHG, Dansercoer A, Gras D, Chanez P, Bachert C, Gonçalves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides SN, Lambrecht BN.

Science. 2019 May 24;364(6442). pii: eaaw4295. doi: 10.1126/science.aaw4295.

PMID:
31123109
2.

Increased expression of IL-24 in chronic spontaneous urticaria.

de Montjoye L, Herman A, Hendrickx E, Chéou P, Blanchetot C, Hofman E, Baeck M, Dumoutier L.

Allergy. 2019 Apr 21. doi: 10.1111/all.13832. [Epub ahead of print] No abstract available.

PMID:
31006117
3.

A bispecific antibody strategy to target multiple type 2 cytokines in asthma.

Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, Blanchetot C, Lambrecht BN.

J Allergy Clin Immunol. 2018 Oct;142(4):1185-1193.e4. doi: 10.1016/j.jaci.2018.06.002. Epub 2018 Jun 8.

PMID:
29890236
4.

Therapeutic bispecific antibody formats: a patent applications review (1994-2017).

Godar M, de Haard H, Blanchetot C, Rasser J.

Expert Opin Ther Pat. 2018 Mar;28(3):251-276. doi: 10.1080/13543776.2018.1428307. Epub 2018 Jan 25. Review.

PMID:
29366356
5.

Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.

Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G.

MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14. Review.

6.

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Godar M, Morello V, Sadi A, Hultberg A, De Jonge N, Basilico C, Hanssens V, Saunders M, Lambrecht BN, El Khattabi M, de Haard H, Michieli P, Blanchetot C.

Sci Rep. 2016 Aug 22;6:31621. doi: 10.1038/srep31621.

7.

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops.

van der Woning B, De Boeck G, Blanchetot C, Bobkov V, Klarenbeek A, Saunders M, Waelbroeck M, Laeremans T, Steyaert J, Hultberg A, De Haard H.

MAbs. 2016 Aug-Sep;8(6):1126-35. doi: 10.1080/19420862.2016.1189050. Epub 2016 May 21.

8.

Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies.

Blanchetot C, De Jonge N, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, de Haard H.

J Biol Chem. 2016 Jun 24;291(26):13846-54. doi: 10.1074/jbc.M115.695528. Epub 2016 Apr 27.

9.

Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.

Klarenbeek A, Blanchetot C, Schragel G, Sadi AS, Ongenae N, Hemrika W, Wijdenes J, Spinelli S, Desmyter A, Cambillau C, Hultberg A, Kretz-Rommel A, Dreier T, De Haard HJ, Roovers RC.

Protein Eng Des Sel. 2016 Apr;29(4):123-33. doi: 10.1093/protein/gzw003. Epub 2016 Mar 5.

PMID:
26945588
10.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

11.

Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.

Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, Roovers RC, Cambillau C, Spinelli S, Del-Favero J, Verrips T, de Haard HJ, Achour I.

MAbs. 2015;7(4):693-706. doi: 10.1080/19420862.2015.1046648.

12.

Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.

McCoy LE, Groppelli E, Blanchetot C, de Haard H, Verrips T, Rutten L, Weiss RA, Jolly C.

Retrovirology. 2014 Oct 2;11:83. doi: 10.1186/s12977-014-0083-y.

13.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P.

J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27.

14.

Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.

Blanchetot C, Verzijl D, Mujić-Delić A, Bosch L, Rem L, Leurs R, Verrips CT, Saunders M, de Haard H, Smit MJ.

J Biol Chem. 2013 Aug 30;288(35):25173-82. doi: 10.1074/jbc.M113.467969. Epub 2013 Jul 8.

15.

Kinetics of PKCε activating and inhibiting llama single chain antibodies and their effect on PKCε translocation in HeLa cells.

Summanen M, Granqvist N, Tuominen RK, Yliperttula M, Verrips CT, Boonstra J, Blanchetot C, Ekokoski E.

PLoS One. 2012;7(4):e35630. doi: 10.1371/journal.pone.0035630. Epub 2012 Apr 20.

16.

The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon.

Paalanen MM, Ekokoski E, El Khattabi M, Tuominen RK, Verrips CT, Boonstra J, Blanchetot C.

Eur J Pharm Sci. 2011 Mar 18;42(4):332-9. doi: 10.1016/j.ejps.2010.12.012. Epub 2011 Jan 8.

PMID:
21220006
17.

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70. doi: 10.1073/pnas.1012865107. Epub 2010 Nov 8.

18.

Receptor tyrosine phosphatase sigma (RPTPσ) regulates, p250GAP, a novel substrate that attenuates Rac signaling.

Chagnon MJ, Wu CL, Nakazawa T, Yamamoto T, Noda M, Blanchetot C, Tremblay ML.

Cell Signal. 2010 Nov;22(11):1626-33. doi: 10.1016/j.cellsig.2010.06.001. Epub 2010 Jun 12.

PMID:
20550964
19.

The ROS-NOX connection in cancer and angiogenesis.

Blanchetot C, Boonstra J.

Crit Rev Eukaryot Gene Expr. 2008;18(1):35-45. Review.

PMID:
18197784
20.

Caspase-3 regulates catalytic activity and scaffolding functions of the protein tyrosine phosphatase PEST, a novel modulator of the apoptotic response.

Hallé M, Liu YC, Hardy S, Théberge JF, Blanchetot C, Bourdeau A, Meng TC, Tremblay ML.

Mol Cell Biol. 2007 Feb;27(3):1172-90. Epub 2006 Nov 27.

21.

Degradation of the hexose transporter Hxt5p in Saccharomyces cerevisiae.

van Suylekom D, van Donselaar E, Blanchetot C, Do Ngoc LN, Humbel BM, Boonstra J.

Biol Cell. 2007 Jan;99(1):13-23.

PMID:
16928197
22.

Regulation of receptor protein-tyrosine phosphatase dimerization.

van der Wijk T, Blanchetot C, den Hertog J.

Methods. 2005 Jan;35(1):73-9.

PMID:
15588988
23.

Substrate-trapping techniques in the identification of cellular PTP targets.

Blanchetot C, Chagnon M, Dubé N, Hallé M, Tremblay ML.

Methods. 2005 Jan;35(1):44-53.

PMID:
15588985
24.

Editorial.

Blanchetot C, Tremblay ML.

Methods. 2005 Jan;35(1):1. No abstract available.

PMID:
15588979
25.

Receptor protein-tyrosine phosphatase dimerization.

den Hertog J, van der Wijk T, Tertoolen LG, Blanchetot C.

Methods Enzymol. 2003;366:224-40. No abstract available.

PMID:
14674252
26.

Redox-regulated rotational coupling of receptor protein-tyrosine phosphatase alpha dimers.

van der Wijk T, Blanchetot C, Overvoorde J, den Hertog J.

J Biol Chem. 2003 Apr 18;278(16):13968-74. Epub 2003 Feb 11.

27.

Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases.

Blanchetot C, Tertoolen LG, Overvoorde J, den Hertog J.

J Biol Chem. 2002 Dec 6;277(49):47263-9. Epub 2002 Oct 9.

28.

Multimerization of the protein-tyrosine phosphatase (PTP)-like insulin-dependent diabetes mellitus autoantigens IA-2 and IA-2beta with receptor PTPs (RPTPs). Inhibition of RPTPalpha enzymatic activity.

Gross S, Blanchetot C, Schepens J, Albet S, Lammers R, den Hertog J, Hendriks W.

J Biol Chem. 2002 Dec 13;277(50):48139-45. Epub 2002 Oct 2.

29.

Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress.

Blanchetot C, Tertoolen LG, den Hertog J.

EMBO J. 2002 Feb 15;21(4):493-503.

30.

Dimerization of receptor protein-tyrosine phosphatase alpha in living cells.

Tertoolen LG, Blanchetot C, Jiang G, Overvoorde J, Gadella TW Jr, Hunter T, den Hertog J.

BMC Cell Biol. 2001;2:8. Epub 2001 Jun 1.

31.
32.

Identification of p130cas as an in vivo substrate of receptor protein-tyrosine phosphatase alpha.

Buist A, Blanchetot C, Tertoolen LG, den Hertog J.

J Biol Chem. 2000 Jul 7;275(27):20754-61.

34.

Receptor protein-tyrosine phosphatase signalling in development.

den Hertog J, Blanchetot C, Buist A, Overvoorde J, van der Sar A, Tertoolen LG.

Int J Dev Biol. 1999;43(7):723-33. Review.

35.
36.

Supplemental Content

Loading ...
Support Center